DARE - Daré Bioscience, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
DARE price evolution
DARE
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.9 | $4.39 | $11.64 | |
| Short term investments | ||||
| Net receivables | $0.52 | $0.9 | $1.39 | $0.95 |
| Inventory | ||||
| Total current assets | $14.95 | $20.83 | $9.98 | $17.54 |
| Long term investments | ||||
| Property, plant & equipment | $2.03 | $1.77 | $1.61 | $1.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.78 | $3.03 | $3.74 | |
| Total investments | ||||
| Total assets | $18.06 | $23.61 | $13.01 | $21.28 |
| Current liabilities | ||||
| Accounts payable | $1.05 | $1.91 | $4.05 | $3.39 |
| Deferred revenue | $1 | $1 | $1 | |
| Short long term debt | $0.49 | $0.47 | $0.47 | |
| Total current liabilities | $13.16 | $14.59 | $17.72 | $20.48 |
| Long term debt | $1.04 | $1.17 | $0.94 | |
| Total noncurrent liabilities | $6.34 | $6.29 | $5.85 | |
| Total debt | $1.52 | $1.64 | $1.4 | |
| Total liabilities | $19.54 | $20.93 | $24.01 | $26.33 |
| Shareholders' equity | ||||
| Retained earnings | -$169.78 | -$165.08 | -$177.99 | -$171.24 |
| Other shareholder equity | -$0.36 | -$0.39 | -$0.4 | -$0.36 |
| Total shareholder equity | $2.67 | -$11 | -$5.05 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.64 | $34.67 | $51.67 | $4.67 |
| Short term investments | ||||
| Net receivables | $0.95 | $1.7 | $1.15 | $0.46 |
| Inventory | ||||
| Total current assets | $17.54 | $43.04 | $55.3 | $6.98 |
| Long term investments | ||||
| Property, plant & equipment | $1.98 | $0.52 | $0.03 | $0.04 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.74 | $0.79 | $0.51 | $0.57 |
| Total investments | ||||
| Total assets | $21.28 | $43.83 | $55.81 | $7.55 |
| Current liabilities | ||||
| Accounts payable | $3.39 | $2.03 | $2.1 | $1.02 |
| Deferred revenue | $1 | $1 | $1 | $1 |
| Short long term debt | $0.47 | $0.4 | $0.27 | $0.71 |
| Total current liabilities | $20.48 | $31.62 | $16.05 | $7.66 |
| Long term debt | $0.94 | $0.09 | $0.04 | |
| Total noncurrent liabilities | $5.85 | $1.09 | $1 | $1.04 |
| Total debt | $1.4 | $0.49 | $0.27 | $0.76 |
| Total liabilities | $26.33 | $32.71 | $17.05 | $8.7 |
| Shareholders' equity | ||||
| Retained earnings | -$171.24 | -$141.07 | -$110.13 | -$71.43 |
| Other shareholder equity | -$0.36 | -$0.35 | -$0.15 | -$0.09 |
| Total shareholder equity | -$5.05 | $11.11 | $38.75 | -$1.15 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.04 | $0.02 | $0.01 | $1.81 |
| Cost of revenue | $0.03 | $0.01 | ||
| Gross Profit | $0.04 | -$0 | $0 | $1.81 |
| Operating activities | ||||
| Research & development | $4.91 | $3.33 | $3.8 | |
| Selling, general & administrative | $2.45 | $2.67 | $3.15 | |
| Total operating expenses | $4.72 | $7.36 | $6.02 | $6.98 |
| Operating income | -$7.36 | -$6.02 | -$5.17 | |
| Income from continuing operations | ||||
| EBIT | $12.91 | -$6.76 | -$5.06 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.7 | $12.91 | -$6.76 | -$5.06 |
| Income (for common shares) | $12.91 | -$6.76 | -$5.06 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.81 | $10 | ||
| Cost of revenue | ||||
| Gross Profit | $2.81 | $10 | ||
| Operating activities | ||||
| Research & development | $21.54 | $30.04 | $30.62 | $20.77 |
| Selling, general & administrative | $12.11 | $11.24 | $8.35 | $6.55 |
| Total operating expenses | $33.75 | $41.39 | $39.07 | $27.4 |
| Operating income | -$30.94 | -$31.39 | -$39.07 | -$27.4 |
| Income from continuing operations | ||||
| EBIT | -$30.16 | -$30.95 | -$38.7 | -$27.4 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$30.16 | -$30.95 | -$38.7 | -$27.4 |
| Income (for common shares) | -$30.16 | -$30.95 | -$38.7 | -$27.41 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $12.91 | -$6.76 | -$5.06 | |
| Operating activities | ||||
| Depreciation | $0.02 | $0.01 | $0.08 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.56 | $0.63 | $0.62 | |
| Total cash flows from operations | $12.9 | -$6.81 | -$8.18 | |
| Investing activities | ||||
| Capital expenditures | -$0.29 | -$0.01 | -$0.61 | |
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.29 | -$0.01 | -$0.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.18 | $0.22 | $0.79 | |
| Net borrowings | -$0.07 | -$0.2 | -$0.2 | |
| Total cash flows from financing | $0.57 | $0.12 | $0.01 | $5.31 |
| Effect of exchange rate | -$0 | $0.01 | -$0.04 | $0.06 |
| Change in cash and equivalents | $0.72 | $12.75 | -$6.85 | -$3.42 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$30.16 | -$30.95 | -$38.7 | -$27.4 |
| Operating activities | ||||
| Depreciation | $0.09 | $0.05 | -$0.07 | -$0.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.53 | $2.16 | $1.6 | $0.74 |
| Total cash flows from operations | -$38.86 | -$18.09 | -$28.76 | -$25.23 |
| Investing activities | ||||
| Capital expenditures | -$0.63 | -$0.06 | -$0.01 | -$0.02 |
| Investments | ||||
| Total cash flows from investing | -$0.63 | -$0.06 | -$0.01 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.65 | $1.34 | $75.85 | $24.76 |
| Net borrowings | $0.27 | $0.37 | ||
| Total cash flows from financing | $15.64 | $1.34 | $75.85 | $25.13 |
| Effect of exchange rate | -$0.01 | -$0.2 | -$0.06 | $0.01 |
| Change in cash and equivalents | -$23.86 | -$17 | $47 | -$0.11 |
News
Fundamentals
| Market cap | $16.75M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 8.55M |
| Revenue | $1.88M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$3.60M |
| Revenue Q/Q | -95.83% |
| Revenue Y/Y | 88.13% |
| P/E ratio | -4.65 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.90 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.42 |
|---|---|
| ROA | -18.98% |
| ROE | N/A |
| Debt/Equity | -5.22 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.14 |
| Quick ratio | N/A |